In a video interview from #ASH25, @VijayaRBhatt1 of @unmc shares the results of a Phase I trial evaluating the novel first-in-class agent ONC201 (dordaviprone) as post-transplant maintenance therapy in AML & MDS.

Find out more by clicking here:
👉

#AMLsm

Phase I trial of ONC201 as post-transplant maintenance for AML and MDS

Vijaya Bhatt, MBBS, University of Nebraska Medical Center, Omaha, NE, discusses the results of a Phase I trial (NC...

ow.ly

At #ASH25, we spoke with the lovely @AbdulhaqHaifaa of @UCSF, who discussed a subgroup analysis from the STARGLO trial evaluating the efficacy of glofitamab plus GemOx versus R-GemOx in transplant-ineligible patients with R/R #DLBCL.

Watch now:
🎥

#LYMsm

Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO

Haifaa Abdulhaq, MD, University of California San Francisco, San Francisco, CA, discusses a subgroup analysis from the...

ow.ly

It was a pleasure to catch up with @LesokhinMD of @MSKCancerCenter at #ASH25 to hear about a post-hoc analysis of the MagnetisMM-3 trial evaluating the feasibility & safety of prolonged elranatamab interruption in R/R #myeloma.

Watch here: 👉

#MMSM

Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis

In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the results of ...

ow.ly

🎥 Adlette Inati of @lebamericanuni presents findings from the first cohort of the ongoing Phase I/II HIBISCUS Kids study, which investigates the PK activator etavopivat in children & adolescents with #SickleCellDisease:

👉 👈

#ASH25 #Hematology #CTSM

Safety and efficacy of etavopivat in adolescents with SCD: the ongoing HIBISCUS Kids trial

Adlette Inati, MD, Lebanese American University, Blat, Lebanon, discusses safety and efficacy findings from the first ...

ow.ly

Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸

Click here: 👉

#MDSsm #CTSM #TrialUpdate #HemOnc

Updated results from a Phase II trial of elritercept in LR-MDS

Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...

ow.ly